First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Feng Guo
- Telefonnummer: 17368707951
- E-Mail: feng.guo@VelaVigo.com
Studienorte
-
-
Queensland
-
Brisbane, Queensland, Australien, 4066
- Icon Cancer Centre Wesley
-
Kontakt:
- Jeffrey Goh
- Telefonnummer: +61 7 3737 4600
- E-Mail: Jeffrey.Goh@icon.team
-
-
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77054
- NEXT Oncology Houston
-
Kontakt:
- Jennifer Segar
- Telefonnummer: +1 (832) 384-7900
- E-Mail: jsegar@nextoncology.com
-
-
Utah
-
West Valley City, Utah, Vereinigte Staaten, 84119
- START Mountain Region, LLC.
-
Kontakt:
- Jose Pacheco
- Telefonnummer: +1 (801) 907-4750
- E-Mail: Jose.pacheco@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- NEXT Oncology Virginia
-
Kontakt:
- Mohamad Salkeni
- Telefonnummer: +1 (703) 783-4510
- E-Mail: malkeni@nextoncology.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- - A participant must meet all of the following inclusion criteria to be eligible to participate in this trial:
- 1. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.
- 2. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment, or standard therapies are not appropriate or not safe in the opinion of the Investigator or refused by the participant.
- 3. At least one measurable lesion as assessed according to RECIST v1.1 criteria for participants with non-pleural mesothelioma or other solid tumors and modified RECIST(mRECIST) for participants with malignant pleural mesothelioma.
- 4. Male or female adults (defined as ≥ 18 years of age)
- 5. ECOG performance status 0-1
- 6. Has LVEF ≥ 50% by either ECHO or MUGA within 28 days before enrollment.
- 7. Life expectancy greater than 12 weeks
- 8. Archived tumor tissue sample available or able to undergo a fresh biopsy collection.
- 9. Adequate organ and bone marrow function
Exclusion Criteria:
- Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment.
- Known or suspected brain metastases, or spinal cord compression.
- Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
- Has a history of underlying pulmonary disorder including.
- History of chronic, active, or hereditary corneal disease.
- Participant history of congestive heart failure (CHF) Class II-IV according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Phase 1 (Dosiserkalation und Hinterfüllung) , Phase 2 (Dosisoptimierung und Kohortenexpansion)
|
VBC106
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of dose-limiting toxicities (DLT) as defined in the protocol
Zeitfenster: (DLT)From time of first dose of VBC106 to end of DLT period (approximately 21 days)
|
Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
|
(DLT)From time of first dose of VBC106 to end of DLT period (approximately 21 days)
|
|
Incidence of Serious Adverse Events
Zeitfenster: From time of Informed Consent to 30 days post last dose of VBC106
|
Number of patients with serious adverse events by system organ class and preferred term
|
From time of Informed Consent to 30 days post last dose of VBC106
|
|
Incidence of Adverse Events (AEs)
Zeitfenster: From time of Informed Consent to 30 days post last dose of VBC106
|
Number of patients with adverse events by system organ class and preferred term
|
From time of Informed Consent to 30 days post last dose of VBC106
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response Rate (ORR)
Zeitfenster: From date of first dose of VBC106 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
|
The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)
|
From date of first dose of VBC106 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
|
|
Duration of Response (DoR)
Zeitfenster: From date of first dose of VBC106 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
|
The time from date of first response until date of disease progression or last evaluable assessment (RECIST v1.1) in the absence of progression
|
From date of first dose of VBC106 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
|
|
Disease Control Rate (DCR) at 12 weeks
Zeitfenster: From date of first dose of VBC106 up until progression, or the last evaluable assessment in the absence of progression (for each patient this is expected to be measured at 12 weeks)
|
The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1) for >=11 weeks from first dose
|
From date of first dose of VBC106 up until progression, or the last evaluable assessment in the absence of progression (for each patient this is expected to be measured at 12 weeks)
|
|
Progression free Survival (PFS)
Zeitfenster: From date of first dose of VBC106 up until date of progression or death due to any cause (approximately 2 years)
|
The time from first dose until RECIST 1.1 defined disease progression or death due to any cause
|
From date of first dose of VBC106 up until date of progression or death due to any cause (approximately 2 years)
|
|
Overall Survival (OS)
Zeitfenster: From date of first dose of VBC106 up until the date of death due to any cause (approximately 2 years)
|
The time from the date of the first dose of study treatment until death due to any cause.
|
From date of first dose of VBC106 up until the date of death due to any cause (approximately 2 years)
|
|
Pharmacokinetics of VBC106: Area under the concentration time curve (AUC)
Zeitfenster: From date of first dose of VBC106 up until 30 days post last dose
|
Measurement of PK parameters: Area under the concentration time curve (AUC)
|
From date of first dose of VBC106 up until 30 days post last dose
|
|
Pharmacokinetics of VBC106: Maximum plasma concentration of the study drug (C-max)
Zeitfenster: From date of first dose of VBC106 up until 30 days post last dose
|
Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)
|
From date of first dose of VBC106 up until 30 days post last dose
|
|
Pharmacokinetics of VBC106: Time to maximum plasma concentration of the study drug (T-max)
Zeitfenster: From date of first dose of VBC106 up until 30 days post last dose
|
Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)
|
From date of first dose of VBC106 up until 30 days post last dose
|
|
Pharmacokinetics of VBC106: Half-life
Zeitfenster: From date of first dose of VBC106 up until 30 days post last dose
|
Measurement of PK parameters: Terminal elimination half-life (t 1/2)
|
From date of first dose of VBC106 up until 30 days post last dose
|
|
Immunogenicity of VBC106: Anti-Drug Antibodies (ADA)
Zeitfenster: From date of first dose of VBC106 up until 30 days post last dose
|
Evaluating the number and percentage of patients who develop Anti-drug antibody (ADA) during treatment
|
From date of first dose of VBC106 up until 30 days post last dose
|
|
Pharmacokinetics of VBC106
Zeitfenster: From date of first dose of VBC106 up until 30 days post last dose
|
Measurement of plasma concentrations of VBC106, total antibody and total unconjugated warhead(measurement unit can be same as ng/ml)
|
From date of first dose of VBC106 up until 30 days post last dose
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- VBC106-01-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .